Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cystic Fibrosis Clear all
Completed Phase 3 Interventional Results available

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

NCT02797132
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LUM/IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years to 5 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Use of Formula Fortified With DHA in Infants With Cystic Fibrosis

NCT00530244
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Docosahexaenoic acid (DHA), Standard formula (Enfamil)
Dietary Supplement
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Up to 56 Days
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Atlanta, Georgia • Des Moines, Iowa + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Impact of Telerehabilitation Training on Pediatric Cystic Fibrosis Patients: An Exploratory Study

NCT02715921
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tele-exercise
Other
Lead sponsor
MemorialCare Health System
Other
Eligibility
8 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Comparison of MRI and Molecular Breast Imaging in Breast Diagnostic Evaluation

NCT00591864
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated No phase listed Observational

Diagnosis and Treatment of Patients With Cystic Fibrosis

NCT00001223
View directory record Official record
Conditions
Cystic Fibrosis, Liver Disease or Abnormalities, Diabetes, Pancreatic Insufficiency (Exocrine and Endocrine)
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
4 Years to 120 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Phase 4 Interventional

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

NCT05548283
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Interventions
Beta-lactam antibiotic, Aminoglycoside
Drug
Lead sponsor
Chris Goss
Other
Eligibility
6 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
59
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)

NCT02343445
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
P-1037, Hypertonic Saline, Saline
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
12 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
33
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting No phase listed Observational

Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome

NCT05982795
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge, Olfactory Function Testing, Survey Completion
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational

Mapping Chemical and Microbiological Heterogeneity Throughout Explanted Cystic Fibrosis Lung Specimens

NCT02128711
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Withdrawn No phase listed Observational

Intermittent Versus Continuous Infusion Meropenem in Cystic Fibrosis

NCT02048163
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Dayton Children's Hospital
Other
Eligibility
7 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 17, 2026, 4:09 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT04306939
View directory record Official record
Conditions
Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions
venipuncture, Questionnaires, Additional Sample Collections
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

BioEnergetics and Metabolomics in Cystic Fibrosis

NCT02225899
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

NCT01641822
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI, Placebo to match AZLI, Tobramycin inhalation solution
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more
Source: ClinicalTrials.gov public record
Updated May 8, 2016 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

NCT02104245
View directory record Official record
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin dispersion for inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 17, 2026, 4:09 AM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

NCT05422222
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
1 Year to 11 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
19
States / cities
Orange, California • Palo Alto, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 4 Interventional Results available

Ext. Long-term Safety Study in CF Patients: Single Arm TIP

NCT01775137
View directory record Official record
Conditions
Long-term Safety of TIP
Interventions
TBM100
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Akron, Ohio • Charleston, South Carolina • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation

NCT01161537
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-770, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis

NCT00763412
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes, Pancreatic Insufficiency
Interventions
placebo, repaglinide
Drug
Lead sponsor
Arbelaez, Ana Maria
Individual
Eligibility
12 Years to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease

NCT00322868
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
pioglitazone
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 17, 2026, 4:09 AM EDT
Active, not recruiting Phase 4 Interventional

Hyperpolarized Imaging for New Treatments

NCT04259970
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Initiation of CFTR Modulator
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Cincinnati, Ohio • Charlottesville, Virginia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational

The EPIC Observational Study

NCT00676169
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
CF Therapeutics Development Network Coordinating Center
Network
Eligibility
Up to 12 Years
Enrollment
1,248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
54
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

NCT00112359
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg three times a day (TID), Placebo three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
40
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting No phase listed Observational

ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)

NCT07505797
View directory record Official record
Conditions
Breast Cancer, Benign Breast Condition, Breast Fibroadenoma, Breast Neoplasms, Breast Disease, Breast Cancer Female, Breast Pain, Breast Cancer Invasive
Interventions
ATUSA 3D Automated Breast Ultrasound System
Device
Lead sponsor
iSono Health, Inc.
Industry
Eligibility
18 Years to 94 Years · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Phase 1 Interventional

Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis

NCT06995651
View directory record Official record
Conditions
Pancreatic Insufficiency, Cystic Fibrosis-related Diabetes
Interventions
Dorzagliatin, Placebo
Drug
Lead sponsor
Michael R. Rickels, MD, MS
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 17, 2026, 4:09 AM EDT